{'fraction_non_alphanumeric': 0.012716763005780347, 'fraction_numerical': 0.009248554913294798, 'mean_word_length': 5.873015873015873, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Managing diabetes and hypertension in chronic kidney disease

Abstract: Since 2020, several guidelines have been published to help health practitioners better manage hypertension and diabetes in patients with chronic kidney disease. Scrutiny on the inclusion of race in determining the estimated glomerular filtration rate (eGFR) as well as breakthrough research regarding the drug dapagliflozin for the treatment of patients with chronic kidney disease are discussed. Since 2020, several guidelines have been published to help health practitioners better manage hypertension and diabetes in patients with chronic kidney disease. Scrutiny on the inclusion of race in determining the estimated glomerular filtration rate (eGFR) as well as breakthrough research regarding the drug dapagliflozin for the treatment of patients with chronic kidney disease are discussed.